These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8541245)

  • 1. Cognitive impairment as a target for pharmacological treatment in schizophrenia.
    Davidson M; Keefe RS
    Schizophr Res; 1995 Sep; 17(1):123-9. PubMed ID: 8541245
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.
    Chung YC; Lee CR; Park TW; Yang KH; Kim KW
    World J Biol Psychiatry; 2009; 10(2):156-62. PubMed ID: 19514097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical antipsychotic drugs improve cognition in schizophrenia.
    Meltzer HY; Sumiyoshi T
    Biol Psychiatry; 2003 Feb; 53(3):265-7; author reply 267-8. PubMed ID: 12559661
    [No Abstract]   [Full Text] [Related]  

  • 5. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
    Mazeh D; Zemishlani H; Barak Y; Mirecki I; Paleacu D
    Int Psychogeriatr; 2006 Sep; 18(3):429-36. PubMed ID: 16478570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions.
    Green MF
    Am J Psychiatry; 2007 Jul; 164(7):992-4. PubMed ID: 17606645
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
    Weiss E; Kemmler G; Fleischhacker WW
    Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
    Keefe RS; Silva SG; Perkins DO; Lieberman JA
    Schizophr Bull; 1999; 25(2):201-22. PubMed ID: 10416727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verbal memory.
    Sumiyoshi T
    Handb Exp Pharmacol; 2015; 228():237-47. PubMed ID: 25977085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender differences in cognition in schizophrenia.
    Perlick D; Mattis S; Stastny P; Teresi J
    Schizophr Res; 1992 Oct; 8(1):69-73. PubMed ID: 1358186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 13. Donepezil for memory dysfunction in schizophrenia.
    Howard AK; Thornton AE; Altman S; Honer WG
    J Psychopharmacol; 2002 Sep; 16(3):267-70. PubMed ID: 12236636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.
    Rossi A; Mancini F; Stratta P; Mattei P; Gismondi R; Pozzi F; Casacchia M
    Acta Psychiatr Scand; 1997 Jan; 95(1):40-3. PubMed ID: 9051159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Current pro-cognitive therapeutic strategies for improved pharmacological treatment in schizophrenia.
    Wadenberg ML
    Curr Pharm Des; 2014; 20(31):5045. PubMed ID: 24345264
    [No Abstract]   [Full Text] [Related]  

  • 17. [Schizophrenia and cognition: long-standing and current issues].
    Azorin JM; Da Fonseca D; Fakra E
    Encephale; 2011 Dec; 37 Suppl 2():S93-4. PubMed ID: 22212848
    [No Abstract]   [Full Text] [Related]  

  • 18. Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia.
    Bromley E
    Psychiatr Serv; 2007 Apr; 58(4):475-81. PubMed ID: 17412848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for cognitive loss and dementia.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):155-161. PubMed ID: 28922342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.